Why the study?
Does AT1 receptor antagonism with candesartan attenuate enhanced tubuloglomerular feedback responses in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension?
Does AT1 receptor antagonism with candesartan attenuate enhanced tubuloglomerular feedback responses in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension?
In a transgenic rat model of inducible malignant hypertension, AT1 receptor activation by ANG II contributes to enhanced tubuloglomerular feedback responsiveness.
Candesartan attenuates enhanced tubuloglomerular feedback in this rat model of malignant hypertension; hypothesis-generating for AT1 effects on TGF in humans.
The present study was performed to evaluate tubuloglomerular feedback responses in transgenic rats [TGR(Cypa1a1Ren2)] with inducible malignant hypertension and to determine the degree to which feedback responsiveness is modulated by ANG II in these rats. Male Cyp1a1-Ren2 rats were fed a normal diet containing the aryl hydrocarbon indole-3-carbinol (I3C; 0.3%), for 5-6 days to stimulate expression of the Cyp1a1-Ren2 transgene and, thereby, to induce malignant hypertension. Stop-flow pressure (SFP) feedback responses to a late proximal perfusion rate of 40 nl/min were assessed in pentobarbital sodium-anesthetized rats during control conditions and after administration of the AT(1) receptor antagonist candesartan (0.1 mg/kg iv). Rats induced with I3C (n = 6) exhibited elevated mean arterial pressure and increased maximal SFP feedback responses compared with noninduced rats (n = 4; 163 +/- 4 vs. 130 +/- 2 mmHg, P < 0.01 and 16.3 +/- 1.4 vs. 11.7 +/- 0.5 mmHg, P < 0.05, respectively). Systemic candesartan decreased arterial pressure (to 98 +/- 7 and to 101 +/- 5 mmHg, respectively, P < 0.001) and attenuated SFP feedback responses (to 2.0 +/- 0.4 and to 3.3 +/- 0.9 mmHg, respectively, P < 0.01) in both hypertensive and normotensive rats. In additional experiments, peritubular capillary infusion of 10(-3) M candesartan did not alter arterial pressure but attenuated feedback responses in both hypertensive (19.3 +/- 1.4 to 8.8 +/- 0.9 mmHg, P < 0.01, n = 9) and normotensive Cyp1a1-Ren2 rats (9.0 +/- 0.8 to 4.7 +/- 0.6 mmHg, P < 0.01, n = 7). The present findings indicate that Cyp1a1-Ren2 rats with ANG II-dependent malignant hypertension exhibit augmented tubuloglomerular feedback responses. The data also show that AT(1) receptor activation by ANG II contributes to the enhanced feedback responsiveness in Cyp1a1-Ren2 rats with malignant hypertension.
No takes yet. Share an insight, caveat, or question.
Mitchell et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: